ArticleEuropean journal of pediatrics2025
The clinical application value of the biomarkers based on autophagy screening in the diagnosis and monitoring of inflammatory bowel disease in pediatric patients.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Inflammatory bowel diseases (IBD) are immune-mediated disorders of children and adults. Autophagy dysfunction has been linked to IBD pathology, and we screened and evaluated the potential biomarkers for pediatric IBD diagnosis and activity evaluation. The autophagy gene expression matrix of IBD samples was obtained via GeneCards and GEO databases. Significant differentially expressed genes were obtained using the R language "limma" package, followed by KEGG enrichment analysis using the "clusterProfile" package. Totally, 95 pediatric IBD patients and 44 controls were selected from Beijing Children's Hospital, with IBD subjects divided into the IBD-Remission and IBD-Activity groups. Peripheral blood autophagy-related gene levels in pediatric IBD patients were determined by RT-qPCR. Autophagy genes that were independently correlated with pediatric IBD occurrence and activity were screened, with their value for diagnosing and monitoring the activity of pediatric IBD assessed. OPTN, GABARAPL2, FKBP8, BNIP3L, and BCL2L1 were obtained as the autophagy-related genes. FKBP8 and BCL2L1 mRNA expression levels were elevated in IBD patients. BCL2L1 was an independent risk factor (IRF) for pediatric IBD occurrence. Peripheral blood BCL2L1 > 0.75 had high auxiliary diagnostic value for pediatric IBD occurrence. BCL2L1 and GABARAPL2 were higher in the IBD-Activity group than in the IBD-Remission group. Peripheral blood BCL2L1 was an IRF for pediatric IBD activity. Peripheral blood BCL2L1 > 1.96 had high auxiliary predictive value for pediatric IBD activity.
conclusionBCL2L1 was an IRF for the occurrence and disease activity of pediatric IBD and had high clinical application value in assisting pediatric IBD diagnosis and predicting disease activity. WHAT IS KNOWN: • Autophagy dysfunction is associated with IBD. • No research reports on the clinical application of autophagy-related biomarkers in the diagnosis and activity monitoring of IBD. WHAT IS NEW: • BCL2L1 was an IRF for the occurrence and disease activity of pediatric IBD. • BCL2L1 had high clinical application value in assisting pediatric IBD diagnosis and predicting disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.